Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Bristol Myers Squibb, the most common co-covered peer. The tracked stories average 2 original sources each. Amprius Technologies appears in 1 tracked Biotech story from March 4, 2026.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Bristol Myers Squibb, the most common co-covered peer. The tracked stories average 2 original sources each. Amprius Technologies appears in 1 tracked Biotech story from March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amprius Technologies. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Amprius Technologies is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
